Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant

Inclusion Criteria: All volunteers must satisfy all the following criteria to be eligible for the study * Healthy adults, adolescents and children based on medical history, physical examination and baseline blood tests * Age: 5-45 years of age at the time of enrollment (i.e. up to the day before their 46th birthday). * Signed informed consent/thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the participant to join the trial (if under the age of 18). For participants aged 18 and above, signed informed consent/thumb-printed of the participant. * Signed informed assent/thumb-printed and witnessed assent obtained from participants (for age group 12-17 years old only). * The investigator believes that the participant and their parents/guardians (if participant aged under 18) can and will comply with the requirements of the protocol. * The participant is a permanent resident of the study area and likely to remain a resident for the duration of the trial. * Agreement to refrain from blood donation for the duration of the study * Female participants of childbearing potential (WOCBP) must agree to avoid pregnancy during the duration of the study and practice continuous effective contraception if sexually active. Acceptable forms of contraception for female volunteers of childbearing potential include: * Established use of oral, injected or implanted hormonal methods of contraception. * Placement of an intrauterine device (IUD) or intrauterine…